Recent advances in the development of broad-spectrum antiprotozoal agents

Antonio Moreno-Herrera, Sandra Cortez-Maya, Virgilio Bocanegra-Garcia, Bimal Krishna Banik, Gildardo Rivera

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Infections caused by Trypanosoma brucei, Trypanosoma cruzi, Leishmania spp., Enta-moeba histolytica, Giardia lamblia, Plasmodium spp., and Trichomonas vaginalis, are part of a large list of human parasitic diseases. Together, they cause more than 500 million infections per year. These protozoa parasites affect both low-and high-income countries and their pharmacological treatments are limited. Therefore, new and more effective drugs in preclinical development could improve overall therapy for parasitic infections even when their mechanisms of action are unknown. In this review, a number of heterocyclic compounds (diamidine, guanidine, quinoline, benzimidaz-ole, thiazole, diazanaphthalene, and their derivatives) reported as antiprotozoal agents are discussed as options for developing new pharmacological treatments for parasitic diseases.

Original languageEnglish
Pages (from-to)583-606
Number of pages24
JournalCurrent Medicinal Chemistry
Issue number3
StatePublished - 2021


  • Antiprotozoal
  • Drugs
  • Entamoeba histolytica
  • Giardia lamblia
  • Leishmania spp
  • Plasmodium spp
  • Trichomonas vaginalis
  • Trypanosoma brucei
  • Trypanosoma cruzi


Dive into the research topics of 'Recent advances in the development of broad-spectrum antiprotozoal agents'. Together they form a unique fingerprint.

Cite this